EUTILEX
Eutilex Co., Ltd. develops biotechnology. The Company develops immunotherapy technology, anti tumor T cell therapy and antibody therapeutics, and other technology products. Eutilex markets its products throughout South Korea.
EUTILEX
Industry:
Biopharma Biotechnology Medical
Founded:
2015-01-01
Address:
Seoul, Seoul-t'ukpyolsi, South Korea
Country:
South Korea
Website Url:
http://www.eutilex.com
Total Employee:
11+
Status:
Active
Total Funding:
21 B KRW
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Mobile Non Scaleable Content Euro IIS Sectigo SSL Sectigo Domain SSL
Similar Organizations
Numab
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.
Rainier Therapeutics
Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.
Current Employees Featured
Byoung Kwon CEO @ Eutilex
CEO
Founder
Investors List
SNU Bio Angel
SNU Bio Angel investment in Series A - Eutilex
G.N. Tech Venture
G.N. Tech Venture investment in Series A - Eutilex
Kolon Investment
Kolon Investment investment in Series A - Eutilex
DS Asset Management
DS Asset Management investment in Series A - Eutilex
Official Site Inspections
http://www.eutilex.com
- Host name: mail179.webmaker21.kr
- IP address: 115.68.17.179
- Location: South Korea
- Latitude: 37.5112
- Longitude: 126.9741
- Timezone: Asia/Seoul
More informations about "Eutilex"
Eutilex - Crunchbase Company Profile & Funding
Eutilex is a develops immunotherapy technology, anti tumor T cell therapy and antibody therapeutics, and other technology products. ... Products. Resources. Pricing. Resources. Log …See details»
(주)유틸렉스
Eutilex 유틸렉스는 끊임 없는 연구 개발을 통하여 면역치료를 통한 혁신 치료제 개발을 위해 노력하고 있습니다.. 유틸렉스 소개; CEO인사말See details»
Eutilex Company Profile - Office Locations, Competitors ... - Craft
Oct 11, 2024 Eutilex has 3 employees at their 1 location and ₩131.65 m in annual revenue in FY 2023. See insights on Eutilex including office locations, competitors, revenue, financials, …See details»
Eutilex Company Profile 2024: Stock Performance & Earnings
Eutilex Co Ltd is a Korean that operates in the anti-tumor immunotherapy market. The company develops anti-tumor T cell therapy and antibody therapeutics based on its immunotherapy …See details»
Eutilex - VentureRadar
Eutilex is developing anti-tumor T cell therapy and immuno-oncology antibody therapeutics based on its own proprietary immuno-oncology technology. An R&D oriented biotech in South Korea, …See details»
Eutilex - Overview, News & Similar companies | ZoomInfo.com
Eutilex and Huahai Enter Immuno-Oncology Partnership SEOUL, South Korea, Nov. 6, 2017 /PRNewswire/ -- Eutilex Co. Ltd. today announced that it has entered into a strategic …See details»
Eutilex Co. Ltd. - VentureRadar
Eutilex is a biotechnology company focused on the research and development of innovative T-cell, chimeric antigen receptor (CAR) T-cell and antibody therapies for cancer and …See details»
Eutilex - Crunchbase
Eutilex is a develops immunotherapy technology, anti tumor T cell therapy and antibody therapeutics, and other technology products. Search Crunchbase. ... A Contract Development …See details»
Eutilex - Funding, Financials, Valuation & Investors - Crunchbase
Eutilex is a develops immunotherapy technology, anti tumor T cell therapy and antibody therapeutics, and other technology products. Search Crunchbase. ... How much funding has …See details»
Byoung S. Kwon, CEO – Eutilex - PharmaBoardroom
Sep 6, 2022 Eutilex’s CEO, Byoung S. Kwon, outlines the company’s approach to cancer research, including its antibodies and CAR-T-centred pipeline and focus on unmet needs. He …See details»
Using immunology to bring new paradigms to oncology therapies
Founded in 2015 and based in Seoul, South Korea, Eutilex is a biotechnology company focused on the research and development of innovative T cell, chimeric antigen receptor (CAR) T cell …See details»
Using immunology to bring new paradigms to oncology therapies
Eutilex is developing preclinical and clinical-stage immunotherapeutics using its three in-house plat-form technologies. Eutilex’s CEO, Byoung S. Kwon, is a leading immuno-oncology …See details»
Samsung Biologics Signs CDO Deal with Eutilex
Samsung Biologics signed on March 20 a contract development organization (CDO) agreement with Eutilex for developing cancer immunotherapy medicine. The signing ceremony was held …See details»
Samsung Biologics, National OncoVenture, and Eutilex Obtain IND ...
Jan 27, 2021 About Eutilex, Ltd. Eutilex (KOSDAQ:263050) is a biotechnology company focused on the research and development of three in-house immunotherapeutic platforms, including …See details»
Eutilex - Updates, News, Events, Signals & Triggers - Crunchbase
Eutilex is a develops immunotherapy technology, anti tumor T cell therapy and antibody therapeutics, and other technology products.See details»
Eutilex and Huahai Enter Immuno-Oncology Strategic Partnership …
SEOUL, South Korea, Nov. 6, 2017 /PRNewswire/ — Eutilex Co. Ltd. today announced that it has entered into a strategic partnership with China’s fast-growing Zhejiang Huahai Pharmaceutical …See details»
GenScript ProBio and Eutilex Enter into Exclusive Strategic ...
Apr 7, 2020 Eutilex is positioning itself to be a leading biotechnology company in the anti-tumor immunotherapy markets through its ground-breaking technical innovation and continues to …See details»
Research programme: adoptive T-cell therapies - Eutilex
Dec 28, 2021 Eutilex is developing adoptive T cell therapies (4-1BB CTL) that isolate tumour-specific CD8+ T cells from the patient's own peripheral blood based on Research programme: …See details»
Samsung Biologics, National OncoVenture, and Eutilex obtains IND ...
Jan 27, 2021 Studied by NOV and Eutilex with humanized mice, EU101(NOV1801), effectively eradicated human tumors and showed synergistic anti-tumor activity with immune checkpoint …See details»
WT-induced adoptive T cell therapy - Eutilex - AdisInsight - Springer
Eutilex is developing an adoptive T cell therapy (4-1BB CTL) that isolates tumour-specific CD8+ T cells from the patient's own peripheral blood based on Wilm's WT-induced adoptive T cell …See details»